Bibliometrics Analysis of Studies on Hypertrophic Cardiomyopathy From 2018 to 2022

Tao LU, Zhengyang LU, Yanhai MENG, Changsheng ZHU, Zining WU, Shuiyun WANG

Acta Academiae Medicinae Sinicae ›› 2024, Vol. 46 ›› Issue (3) : 377-383.

PDF(1609 KB)
Home Journals Acta Academiae Medicinae Sinicae
Acta Academiae Medicinae Sinicae

Abbreviation (ISO4): Acta Academiae Medicinae Sinicae      Editor in chief: Xuetao CAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(1609 KB)
Acta Academiae Medicinae Sinicae ›› 2024, Vol. 46 ›› Issue (3) : 377-383. DOI: 10.3881/j.issn.1000-503X.15892
Original Articles

Bibliometrics Analysis of Studies on Hypertrophic Cardiomyopathy From 2018 to 2022

Author information +
History +

Abstract

Objective to analyze the research progress and hot topics in hypertrophic cardiomyopathy from 2018 to 2022.Methods the publications in the field of hypertrophic cardiomyopathy from January 1,2018 to December 31,2022 were retrieved from Web of Science core collection database and included for a bibliometric analysis.results A total of 6355 publications were included,with an average citation frequency of 7 times.the year 2021 witnessed the most publications(1406).the analysis with VOSviewer showed that the research on sudden death related to hypertrophic cardiomyopathy,especially the predictive value of late gadolinium-enhanced cardiac MRI in sudden death,was a hot topic.in addition,gene detection and the new drug mavacamten became hot research topics.the United States was the country with the largest number of publications and the highest citation frequency in this field.Chinese scholars produced the second largest number of publications,which,however,included few high-quality research results.Conclusions Risk stratification and prevention of sudden death is still an important and hot research content in the field of hypertrophic cardiomyopathy.Chinese scholars should carry out multi-center cooperation in the future to improve the research results。

Key words

hypertrophic cardiomyopathy / sudden death / gene / mavacamten / bibliometrics

Cite this article

Download Citations
Tao LU , Zhengyang LU , Yanhai MENG , et al . Bibliometrics Analysis of Studies on Hypertrophic Cardiomyopathy From 2018 to 2022[J]. Acta Academiae Medicinae Sinicae. 2024, 46(3): 377-383 https://doi.org/10.3881/j.issn.1000-503X.15892

References

[1]
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2020, 142(25):e558-e631.DOI:10.1161/CIR.0000000000000937.
[2]
Johnson MH, Cohen J, Grudzinskas G. The uses and abuses of bibliometrics[J]. Reprod Biomed Online, 2012, 24(5):485-486.DOI:10.1016/j.rbmo.2012.03.007.
[3]
刘启元, 叶鹰. 文献题录信息挖掘技术方法及其软件SATI的实现—以中外图书情报学为例[J]. 信息资源管理学报, 2012, 2(1):50-58.DOI:10.13365/j.jirm.2012.01.012.
[4]
Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy:insights from the sarcomeric human cardiomyopathy registry (SHaRe)[J]. Circulation, 2018, 138(14):1387-1398.DOI:10.1161/CIRCULATIONAHA.117.033200.
[5]
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet, 2020, 396(10253):759-769.DOI:10.1016/s0140-6736(20)31792-x.
[6]
Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy[J]. JAMA Cardiol, 2019, 4(7):644-657.DOI:10.1001/jamacardio.2019.1391.
[7]
Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes[J]. Circ Genom Precis Med, 2019, 12(2):e002460.DOI:10.1161/circgen.119.002460.
[8]
Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A, 2018, 115(35):E8143-E8152.DOI:10.1073/pnas.1809540115.
[9]
Morscher RJ, Ducker GS, Li SH-J, et al. Mitochondrial translation requires folate-dependent tRNA methylation[J]. Nature, 2018, 554(7690):128-132.DOI:10.1038/nature25460.
[10]
O’Mahony C, Jichi F, Ommen SR, et al. International external validation study of the 2014 European Society of Cardiology Guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM)[J]. Circulation, 2018, 137(10):1015-1023.DOI:10.1161/circulationaha.117.030437.
[11]
Mosqueira D, Mannhardt I, Bhagwan JR, et al. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias,hypocontractility,and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy[J]. Eur Heart J, 2018, 39(43):3879-3892.DOI:10.1093/eurheartj/ehy249.
[12]
Ceyhan-Birsoy O, Murry JB, Machini K, et al. Interpretation of genomic sequencing results in healthy and ill newborns:results from the BabySeq Project[J]. Am J Hum Genet, 2019, 104(1):76-93.DOI:10.1016/j.ajhg.2018.11.016.
[13]
Scott MKD, Quinn K, Li Q, et al. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases:a retrospective,multicentre cohort study[J]. Lancet Respir Med, 2019, 7(6):497-508.DOI:10.1016/s2213-2600(18)30508-3.
[14]
Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults.Echocardiographic analysis of 4111 subjects in the CARDIA Study.Coronary artery risk development in (young) adults[J]. Circulation, 1995, 92(4):785-789.DOI:10.1161/01.cir.92.4.785.
[15]
国家心血管病中心心肌病专科联盟、 中国医疗保健国际交流促进会心血管病精准医学分会中国成人肥厚型心肌病诊断与治疗指南专家组. 中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国循环杂志, 2023, 38(1):1-33.DOI:10.3969/j.issn.1000-3614.2023.01.001.
[16]
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy:genetics,pathogenesis,clinical manifestations,diagnosis,and therapy[J]. Circ Res, 2017, 121(7):749-770.DOI:10.1161/CIRCRESAHA.117.311059.
PDF(1609 KB)

Accesses

Citation

Detail

Sections
Recommended

/